BYD Launched BAO 5 under Its New Brand FANGCHENGBAO and the DMO Technology
4.9.2023 12:43:00 EEST | Business Wire | Press release
BYD, the world’s leading manufacturer of new energy vehicles and power batteries, introduced FANGCHENGBAO, its new professional personalized sub-brand, as well as its sophisticated technology: the Dual Mode Off-road (DMO) Super Hybrid Platform. The first model of the new brand - BAO 5, a super hybrid off-road SUV harnessing the DMO technology was launched during the event as well as a concept car BAO 8 and BAO 3.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230817807422/en/
Wang Chuanfu, the Chairman and President of BYD (Photo: Business Wire)
Wang Chuanfu, the Chairman and President of BYD, said at the launch event that FANGCHENGBAO aspires to redefine vehicular experience by offering an unparalleled blend of professionalism and personalization to global users, driving a profound "revolution" in the NEV landscape, transforming cars into unique, tailor-made assets for every individual.
The Brand: A great leap in New Energy Vehicle Sector
The brand name FANGCHENGBAO, derived from Chinese phonetics, symbolizes a blend of precision ("FANGCHENG" for "formula") and agility ("BAO" for "leopard"), introducing a series of specialized technologies, including the DMO Super Hybrid Off-Road Platform, which is also inaugurated at the event.
FANGCHENGBAO envisions the confluence of state-of-the-art new energy technologies and diverse users' preferences will unlock unprecedented user experience: whether journeying through the vast wilderness, speeding on a racetrack, navigating through bustling cityscapes, or cruising on highways; whether seeking occasional exhilaration or traversing daily commutes, an exclusive driving experience for every scenario is now within reach.
To meet this end, FANGCHENGBAO will integrate BYD's apex technologies, forward-looking designing ethos, and the vertically integrated supply chain system, in order to enrich every vehicle with distinctive tailor-made possibilities.
FANGCHENGBAO symbolizes the fusion of new energy and boundless possibilities, turning every individual's dreams into tangible reality.
The DMO Technology: Unleashing the Might of Electricity for Individual Empowerment
At the event, BYD unveiled the innovative DMO Super Hybrid Off-Road Platform, signaling a significant pivot from traditional gasoline engines. This platform powers the FANGCHENGBAO vehicles, promising a transformative off-road experience while championing energy efficiency, and empowering every user with pinnacle technology.
The DMO combines BYD's Revolutionary Non-Load-Bearing Frame Designed for Hybrids with a specialized off-road hybrid architecture. This integration taps into BYD's expertise in high-performance chassis, intelligent electric four-wheel drive, and off-road powertrains. As a result, DMO strikes an unparalleled balance between vehicle safety, powerful off-roading, and energy consumption.
Instead of traditional modifications that add weight and increase rollover risks, the DMO innovatively fuses the Blade Battery and high-strength steel frame, evolving to the Cell to Chassis (CTC) technology. This not only ensures battery safety during extreme off-road scenarios but also significantly boosts overall vehicle safety.
The platform also boasts features like the longitudinal EHS electric hybrid system and an industry-first off-road rear-drive powertrain, as well as the Xiaoyun longitudinal high-performance engine, delivering a formidable system power of more than 500kW and an unmatched traction of 32,000N. Moreover, DMO vehicles utilize intelligent torque control technology to minimize the turning radius to just 3.4 meters. Also thanks to its powerful drive and precise electronic control, users can effortlessly navigate through swampy terrains, rugged mountains, gravelly slopes, and many other extreme terrains with the DMO. Equipped with three Differential Locks, drivers can switch to low-speed gear, which is designed for off-road scenario, with a push on the button.
Building on this innovative architecture, DMO incorporates a double-wishbone independent suspension at both ends, which, when paired with DiSus-P Hydraulic Body Control System, assures SUV-like comfort even in challenging terrains. The platform achieves 35% fuel savings compared to gasoline-powered off-road vehicles.
DMO stands out as a predominantly electric-driven, professional-grade off-road platform. It represents the culmination of over twenty years of BYD's cutting-edge technological evolution and insights from the experience gleaned from millions of BYD PHEVs. This platform transcends the conventional and substantially amplifies the capabilities of electric mobility. With its vast technical prowess, the DMO surmounts challenges that new energy vehicles typically encountered across scenarios, recalibrating the paradigm for off-road vehicular design and functionality.
Looking ahead, FANGCHENGBAO is set to venture into domains such as off-road SUVs and sports cars, where traditional gasoline vehicles predominate, starting from models with the DMO platform.
The New Models: Pioneers With Leading Technology and Unique Product Offerings
Three FANGCHENGBAO's models offer a powerful product lineup, catering to a range of individual preferences, demonstrating its robust product matrix and its dedication to professionalism and individuality.
The BAO 5, positioned as a super hybrid off-road SUV, is equipped with key technologies like DMO and DiSus-P Hydraulic body control system. Its design seamlessly combines industrial aesthetics with robust power, delivering unparalleled stability and safety for users.
As a brand emphasizing customization, FANGCHENGBAO offers the BAO 5 a variety of front-face structures that can be seamlessly integrated or adjusted. It provides a flexible foundation tailored to each user's unique modification preferences.
The BAO 8 concept car, named SUPER 8, unveils the brand's futuristic vision for off-road SUVs. Inspired by sci-fi battlefields, this design ensures robust integration and enhanced protection, inspiring driver confidence. Furthermore, preliminary details about the BAO 3 were revealed, hinting at a trendy model geared towards diverse audiences with a playful spirit.
To ensure consistent service and experience quality, FANGCHENGBAO will adopt a Direct-to-Consumer (DTC) model in the initial phase in the Chinese market, planning to reach 60 cities by 2024. It is also announced that the BAO 5 will have its first offline debut at the Chengdu Motor Show, starting August 25th.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230817807422/en/
Contact information
Asia-Pacific: Liya Huang, pr@byd.com tel: +86-755-8988-8888-69666
Europe: Penny Peng, PressEU@byd.com tel: +31-102070888
North America: Frank Girardot, frank.girardot@byd.com tel: +1 213 245 6503
Latin America: José Miranda, jose.miranda@byd.com
tel: +56 9 96443906
Brazil: Pablo Toledo, pablo.toledo@byd.com tel: +19 3514 2554
Middle East and Africa: Nikki Li, li.namin@byd.com tel: +86-18938862670
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom